Duke In Process To Restart Three Trials Using Microarray Analysis Of Tumors

From The Cancer Letter, Jan. 29, 2010:

Duke University said it is in the process of restarting three clinical trials using microarray analysis of patient tumors to predict their response to chemotherapy.

The university halted the trials to review their scientific underpinnings after a paper in the Annals of Applied Statistics said that the genomic technology developed at Duke and used in the trials incorporated errors and inaccurate calculations and could conceivably put patients at risk (The Cancer Letter, Oct. 2, Oct. 9, Oct. 23, 2009).

In a letter to the editor of The Cancer Letter, Duke officials said that the Institutional Review Board had consulted three directors of cancer centers, who recommended that the patients continue to receive the treatments.

For the rest of the story, click on The Cancer Letter Archive at left to read the Jan. 29 issue (subscription or day pass required).

_____
tags: clinical trials